Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)

Author:

Pastick Katelyn A1ORCID,Okafor Elizabeth C1,Wang Fan2,Lofgren Sarah M1ORCID,Skipper Caleb P1ORCID,Nicol Melanie R2ORCID,Pullen Matthew F1ORCID,Rajasingham Radha1ORCID,McDonald Emily G3,Lee Todd C3,Schwartz Ilan S4,Kelly Lauren E5,Lother Sylvain A6,Mitjà Oriol7,Letang Emili89,Abassi Mahsa1,Boulware David R1

Affiliation:

1. Department of Medicine, University of Minnesota, Minneapolis, Minnesota

2. Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota

3. Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montreal, Canada

4. Division of Infectious Diseases, Department of Medicine, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta

5. Department of Pediatrics and Child Health, Department of Pharmacology, University of Manitoba, Winnipeg, Canada

6. Department of Medicine, Sections of Critical Care and Infectious Diseases, University of Manitoba, Winnipeg, Canada

7. Fight AIDS and Inf Dis Foundation, Hospital Germans Trias i Pujol, Barcelona, Spain

8. Department of Infectious Diseases, Hospital del Mar/Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain

9. ISGlobal, Barcelona Institute for Global Health, Universitat de Barcelona, Barcelona, Spain

Abstract

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we perform a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national and international treatment guidelines.

Funder

National Institute of Mental Health

Doris Duke Charitable Foundation

Fogarty International Center

National Institute of Allergy and Infectious Diseases

Fonds de recherche du Québec – Santé

Fundació Lluita Contra la Sida i les Malalties Infeccioses

Departament de Salut de la Generalitat de Catalunya

Juan Rodés Contract

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Cited by 155 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3